Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort ...
An interim appearance has been scheduled before a hearing panel of the Canadian Investment Regulatory Organization (CIRO) pursuant to the Mutual Fund Dealer Rules in the matter of Michael Alan Kemp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback